Bristol-Myers Squibb and Moffitt Cancer Center Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

Bristol-Myers Squibb and Moffitt Cancer Center have entered into a collaboration agreement as part of Bristol-Myers Squibb's Immuno-Oncology Rare Population Malignancy program.

PRESS RELEASE

NEW YORK & TAMPA, Fla.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Moffitt Cancer Center today announced that they have entered into a collaboration agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S. The I-O RPM program is a multi-institutional initiative with academic-based cancer centers focused on the clinical investigation of immuno-oncology therapeutics as potential treatment options for patients with high risk, poor prognostic cancers, defined as a rare population malignancy.

As part of the I-O RPM program, Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists.

“Moffitt Cancer Center has had a long-standing commitment to immuno-oncology research, including in partnership with Bristol-Myers Squibb, and we look forward to our continued work with them as part of the I-O RPM program,” said Laura Bessen, MD, head of U.S. Medical, Bristol-Myers Squibb.

“This new partnership with Bristol-Myers Squibb will foster new Moffitt investigator-initiated studies for rare tumors and gives our faculty the opportunity to educate research students about innovative clinical trials,” said Dan Sullivan, M.D., Associate Center Director for Clinical Science at Moffitt.